Colinz Laboratories Ltd

Colinz Laboratories has released its financial results for the quarter ending December 2024, highlighting improvements in cash reserves and a strong Debtors Turnover Ratio. However, the company faces challenges with declining operating profit, profit before tax, and earnings per share, indicating a reduction in overall profitability.

Colinz Laboratories has recently undergone a revision in its score by MarketsMOJO, reflecting changes in its financial outlook. Despite a strong operating cash flow and improved debtor turnover, the company faces challenges with long-term growth and profitability metrics. It has been added to MarketsMOJO's list, indicating ongoing interest in its market position.

Colinz Laboratories has recently experienced a revision in its score from MarketsMOJO, reflecting the company's recent positive financial performance. Despite a strong operating cash flow and improved market position, concerns remain regarding its long-term fundamentals and high valuation metrics. Investors are advised to weigh these factors carefully.

Colinz Laboratories, a microcap pharmaceutical company, has announced its financial results for the quarter ending September 2024. Despite being given a 'Sell' call by MarketsMOJO, the company has shown positive performance with the highest annual operating cash flow and quarterly profits in the last five quarters. The company's EPS and liquidity have also improved.

Colinz Laboratories, a microcap pharmaceutical company, has received a 'Sell' rating from MarketsMOJO due to weak long-term fundamentals, high debt, and expensive valuation. Recent performance has been positive, but the majority shareholders being promoters may impact future decisions. Despite market-beating returns, the downgrade raises concerns about long-term potential.

Colinz Laboratories, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO after reporting positive results in September 2024. The company's operating cash flow reached Rs 1.03 crore and cash and cash equivalents were at Rs 8.04 crore. However, its long-term fundamentals are weak and valuation is expensive, with a PEG ratio of 3.1. Investors should carefully consider these factors before making any investment decisions.

Colinz Laboratories, a microcap pharmaceutical company, received a 'Sell' rating from MarketsMOJO on September 11, 2024 due to weak long-term fundamentals, low profitability, and high valuation. However, recent results show promise with increased cash and profits. The stock has outperformed the market and its promoters hold majority shares, indicating potential for future growth.

Colinz Laboratories, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO after reporting positive results in June 2024. The stock has shown improvement in its technical trend and has outperformed the BSE 500 index in the long term. However, its fundamental strength is weak and it is currently trading at an expensive valuation. Investors should carefully consider these factors before investing.

Colinz Laboratories, a microcap pharmaceutical company, received a 'Sell' rating from MarketsMOJO on August 5th, 2024 due to weak long-term fundamentals, poor debt servicing ability, and high valuation. However, the company has shown promising results in June 2024 and has outperformed BSE 500 in the last 3 years, 1 year, and 3 months.

Colinz Laboratories, a microcap pharmaceutical company, has announced its financial results for the quarter ending March 2024. The company's profit after tax and earnings per share were the highest in the last five quarters, showing a positive trend in profitability. However, operating profit and profit before tax were at their lowest, indicating areas for improvement. Investors are advised to hold their stock and monitor future financial reports.

Colinz Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 8th, 2024. The company's consistent growth and strong financials have contributed to this impressive performance, with the stock outperforming the sector by 9.21% and gaining 100.02% in the last 7 days alone. Despite a 'Sell' call from MarketsMOJO, the stock has been trading higher than its moving averages and has outperformed the Sensex by a significant margin in the past year.

Colinz Laboratories, a microcap pharmaceutical company, has seen a remarkable 90.61% increase in returns over the past 7 days, reaching an all-time high of Rs. 81.9 on July 8th, 2024. The stock has also outperformed the sector by 4.07% today and is currently trading higher than its moving averages, showcasing a strong bullish trend. With a growth of 131.91% in the past year, Colinz Laboratories is a promising player in the pharmaceutical industry.

Colinz Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high of Rs.76.8 on July 7th, 2024. Despite a 'Sell' rating from MarketsMOJO, the company has outperformed the sector by 8.75% and has shown consistent growth in the last 6 days. Its 1-year performance has also surpassed the benchmark index, indicating strong potential for growth.

Colinz Laboratories, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching an all-time high of Rs.76.8 on July 6th, 2024. The company has outperformed the sector by 8.75% and has consistently traded higher than its moving averages, showcasing a positive trend. Its success can be attributed to its focus on the resilient pharmaceutical industry.

Colinz Laboratories, a microcap pharmaceutical company, has seen a surge in stock price, reaching a 52-week high of Rs.76.8 on July 5th, 2024. Despite a 'Sell' rating from MarketsMOJO, the stock has outperformed the sector by 5.87% and has been on a consecutive gain for 6 days. It opened with a 10% gap up and is currently trading above its moving averages, indicating a bullish trend. Compared to the Sensex, Colinz Laboratories has shown a remarkable 1-year performance of 97.21%, highlighting its potential for growth in the pharmaceutical industry.

Colinz Laboratories, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching an all-time high of Rs.76.8 on July 5th, 2024. Despite a 'Sell' rating from MarketsMOJO, the company has outperformed the sector by 9.88% and has shown consecutive gains for the last 6 days. Its strong upward trend and impressive 1-year performance of 104.26% make it a promising player in the market.

Colinz Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 4th, 2024. The stock has been consistently performing well, trading higher than its moving averages and showing a remarkable growth of 94.97% in the past year, outperforming the Sensex. However, MarketsMOJO has given a 'Sell' call for the stock.

Colinz Laboratories, a microcap pharmaceutical company, has reached an all-time high in its stock price on July 4th, 2024. The stock has been gaining for the past five days, rising by an impressive 66.36%. Despite a 'Sell' rating from MarketsMOJO, the company has outperformed the sector by 9.71% and has consistently performed well in the past year.

Colinz Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 3rd, 2024. The stock has been on an upward trend for the past four days, gaining 51.25%. It has consistently outperformed the sector and has been trading above its moving averages, making it a stable and promising investment option.